Yarema Kristin
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to Yarema Kristin. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| 0001661460 | President and CEO | U | 615,836 | — | — | Jan 8, 2025 |
| 0001661460 | President and CEO | Award / Grant | 250,000 | — | — | Jan 2, 2024 |
| 0001661460 | President, Cell Therapy | Award / Grant | 356,836 | — | — | Apr 11, 2023 |
| ATRA | Chief Commercial Officer | Award / Grant | 45,533 | — | — | Mar 1, 2022 |
| ATRA | Chief Commercial Officer | Purchase | 2,021 | $14.50 | $29,305 | Jun 14, 2021 |
| ATRA | Chief Commercial Officer | Sale | 761 | $14.55 | $11,073 | May 18, 2021 |
| ATRA | Chief Commercial Officer | Award / Grant | 35,021 | — | — | Mar 1, 2021 |
| ATRA | Chief Commercial Officer | Award / Grant | 55,000 | — | — | Mar 1, 2020 |